Liven Pharma Limited (PSX:LIVEN)

Liven Pharma Income Statement

Financials in millions PKR. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Revenue	127.27	245.09	-	-	-
Revenue Growth (YoY)	-48.07%	-	-	-	-
Cost of Revenue	111.45	182.96	-	-	-
Gross Profit	15.82	62.14	-	-	-
Selling, General & Admin	389.03	19.14	2.12	2.95	2.1
Other Operating Expenses	88.84	1.23	-	-	-
Operating Expenses	507.53	20.37	15.22	17.51	18.19
Operating Income	-491.71	41.77	-15.22	-17.51	-18.19
Interest Expense	-0.73	-0.02	-	-	-
Interest & Investment Income	0.31	-	-	-	-
Other Non Operating Income (Expenses)	-0.06	-0	-0	-0	-0
EBT Excluding Unusual Items	-492.19	41.74	-15.23	-17.51	-18.19
Pretax Income	-492.19	41.74	-15.23	-17.51	-18.19
Income Tax Expense	92.27	-	-2.9	-3.22	-3.55
Net Income	-584.46	41.74	-12.33	-14.29	-14.63
Net Income to Common	-584.46	41.74	-12.33	-14.29	-14.63
Shares Outstanding (Basic)	70	0	12	12	12
Shares Outstanding (Diluted)	70	0	12	12	12
Shares Change (YoY)	174375.69%	-99.67%	-	-	-
EPS (Basic)	-8.37	1043.60	-1.02	-1.18	-1.21
EPS (Diluted)	-8.37	1043.60	-1.02	-1.18	-1.21
Free Cash Flow	-24.56	13.8	-2.27	-2.26	-6.79
Free Cash Flow Per Share	-0.35	345.08	-0.19	-0.19	-0.56
Gross Margin	12.43%	25.35%	-	-	-
Operating Margin	-386.34%	17.04%	-	-	-
Profit Margin	-459.22%	17.03%	-	-	-
Free Cash Flow Margin	-19.30%	5.63%	-	-	-
EBITDA	-465.93	64.93	-2.12	-2.95	-2.1
EBITDA Margin	-	26.49%	-	-	-
D&A For EBITDA	25.78	23.16	13.1	14.56	16.08
EBIT	-491.71	41.77	-15.22	-17.51	-18.19
EBIT Margin	-	17.04%	-	-	-
Advertising Expenses	3.26	0.12	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.